UHS

AI MemoPost-earnings T+1

Universal Health Services

As of 2026-10-28/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q3 earnings: revenue growth, weaker profit • 2026-10-28

Base target: $177 / p=50% prob

Biggest risk

Adjusted EBITDA declined despite revenue growth, both operating segments lost margin, and management expects full-year EBITDA toward the low end of its range. Legal reserves and Medicaid-payment variability complicate earnings quality. [#SEC-8K-2026-10-27] UHS Q3 supplemental disclosures

Invalidation

Break below $150 or thesis failure.

What would change my mind?

Revenue growth, hospital volume and 2026 guidance reaffirmation could support a recovery if margins stabilize. The packet's $195.125 mean target implies about 10% upside from the $177.32 anchor, but its analyst count and currency of revisions are unknown.

Research note

Recommendation

—

Confidence

medium

As of

2026-10-28

Base target

$177

p=50%

Bull target

$205

p=25%

Bear target

$150

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Settlement and Medicaid-payment scrutiny
Hospital volume versus margin pressure
Revenue growth, hospital volume and 2026 guidance reaffirmation could support a recovery if margins stabilize.

BearKey bullets

A tentative litigation settlement drove a $26 million Q3 liability-reserve increase; supplemental Medicaid payments supplied a partly offsetting $47 million benefit.
[#SEC-8K-2026-10-27]
Acute-care and behavioral-health EBITDA margins fell 120 and 260 basis points year over year, respectively.

WatchKey bullets

Q3 earnings: revenue growth, weaker profit

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $177 (p=50%)

Target spread vs base: +16% / -15%

Scenario probabilities

Bull Target: $205 (p=25%)Base Target: $177 (p=50%)Bear Target: $150 (p=25%)

Commentary

Initial coverage reported an approximately 3% after-hours decline following the release, attributing concern to settlement costs and Medicaid-payment uncertainty; this is not a verified full-session reaction. Investing.com report Earnings-surprise framing differs by provider: Investing.com compared $5.22 adjusted EPS with $5.20 consensus, while Zacks reported a miss against $5.31. No verified post-print analyst revisions are incorporated. Social, options, short-interest and employee measures were unavailable; their zero values above are placeholders, not observations.

As of 2026-10-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Settlement and Medicaid-payment scrutiny
Hospital volume versus margin pressure

Scenarios

Bull Target (Scenario probability)

$205 / p=25% prob

Base Target (Scenario probability)

$177 / p=50% prob

Bear Target (Scenario probability)

$150 / p=25% prob

Analysis 2026-10-28 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.30

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-28
Q3 earnings: revenue growth, weaker profit
UHS reported Q3 revenue of $4.733 billion, up 5.3%, but adjusted EPS fell to $5.22 from $5.69 and adjusted EBITDA net of noncontrolling interests fell 6.9%. Consensus comparisons conflict across providers, so the earnings surprise is not a clear bullish signal. [#SEC-8K-2026-10-27] UHS Q3 supplemental disclosures
Prob 100.00% • Move -3.00% • Priced-in 50.00%
EVENT2026-12-31
Lower-end 2026 EBITDA outlook
UHS reaffirmed its July full-year ranges, including adjusted EBITDA net of noncontrolling interests of $2.610 billion–$2.717 billion and adjusted EPS of $22.28–$23.65, but now anticipates EBITDA toward the lower end. Subsequent results will test that narrower expectation. [#SEC-8K-2026-10-27] UHS Q3 supplemental disclosures
Prob 75.00% • Move -4.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Settlement and Medicaid-payment scrutiny
2027-01-26
Q3 included a $47 million favorable Medicaid supplemental-payment impact, partly offset by a $26 million increase in liability reserves primarily related to a tentative litigation settlement. Investors may scrutinize payment durability and residual legal exposure. [#SEC-8K-2026-10-27]
Prob 65% • Move -5% • Priced-in 40%

Long-term Catalysts

Months to a year

Hospital volume versus margin pressure
2027-10-28
Q3 acute-care same-facility revenue grew 4.7%, yet acute-care segment EBITDA margin fell 120 basis points year over year; behavioral-health margin fell 260 basis points. A recovery requires volume and pricing to overcome operating-cost pressure, not merely higher revenue. UHS Q3 supplemental disclosures
Prob 50% • Move 7% • Priced-in 25%

Risks

A tentative litigation settlement drove a $26 million Q3 liability-reserve increase; supplemental Medicaid payments supplied a partly offsetting $47 million benefit. [#SEC-8K-2026-10-27]
Acute-care and behavioral-health EBITDA margins fell 120 and 260 basis points year over year, respectively. UHS Q3 supplemental disclosures
Management expects 2026 adjusted EBITDA net of noncontrolling interests toward the lower end of its reaffirmed range. UHS Q3 supplemental disclosures
The company's forecast reiterates estimated 2026 pre-tax headwinds of $85 million from health-insurance exchanges and $35 million from California nurse-staffing regulation. UHS Q3 supplemental disclosures

Peers

Symbol	Summary
ACHC	Closer comparison for UHS's behavioral-health segment, not its acute-care operations. Acadia SEC filing
HCA	Direct acute-care hospital operating comparison, though larger than UHS; more relevant than the packet's medical-device candidates. HCA Q3 results
THC	Hospital-operator comparison, with a substantial ambulatory-surgery business that limits valuation comparability. Tenet investor release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-28

Loading AI feed…

Symbol

Summary

ACHC

Closer comparison for UHS's behavioral-health segment, not its acute-care operations. Acadia SEC filing

HCA

Direct acute-care hospital operating comparison, though larger than UHS; more relevant than the packet's medical-device candidates. HCA Q3 results

THC

Hospital-operator comparison, with a substantial ambulatory-surgery business that limits valuation comparability. Tenet investor release